Nav: Home

Infrared light to detect early signs of esophageal cancer

September 06, 2016

Scientists have developed an endoscope that uses near-infrared light to spot early warning signs of oesophageal - food pipe - cancer, according to research published in the Journal of Biomedical Optics today.

Researchers at the Cancer Research UK Cambridge Institute sprayed a dye on oesophageal tissue samples taken from people with Barrett's oesophagus - a condition that increases the risk of developing oesophageal cancer. The dye sticks to healthy oesophageal cells but not to pre-cancerous cells.

They then shone near-infrared light on the tissue, which is just beyond the red colours that our eyes can normally see, and used a special camera to detect the near-infrared light the dye gave out.

Researchers had tried this approach before but had used a dye that gave out visible light to spot pre-cancerous cells. Problems arose because when cells are exposed to visible light, they naturally emit visible light themselves - making the distinction between healthy and abnormal cells hard to see.

But, by using a dye that gives out near-infrared light, scientists refined the process so they could make the distinction.

This new technique could be used to monitor people with Barrett's oesophagus who have an increased risk of developing oesophageal cancer, and spot early signs that cancer might be developing before the person has any symptoms.

Dr Sarah Bohndiek, scientist at the Cancer Research UK Cambridge Institute, said: "This research gives us hope for developing better techniques to detect the disease early.

"People who are at a high risk of developing oesophageal cancer, such as those with Barrett's oesophagus, could be closely monitored with this technique. And removing patches of pre-cancerous cells could prevent some cases of oesophageal cancer. But we need to do some further testing before clinical trials with patients can be set up to see how effective the approach could be at saving lives."

There are around 7,800 deaths from oesophageal cancer every year in the UK. For men, oesophageal cancer is the fourth most common cause of cancer death.

Dr Emma Smith, science communication manager at Cancer Research UK, said: "Early detection is crucial if we want to cure more cancers and save more lives. And oesophageal cancer is often caught at an advanced stage, meaning survival rates of the disease have remained stubbornly low.

"We urgently need new ways to detect the disease early. This development could lead to a cheaper, better way of detecting the warning signs of oesophageal cancer and even stop some people developing the disease."
-end-
For media enquiries contact Stephanie McClellan in the Cancer Research UK press office on 020 3469 5314 or, out of hours, on 07050 264 059.

Notes to editor:

*Dale J. Waterhouse ; James Joseph ; André A. Neves ; Massimiliano di Pietro ; Kevin M. Brindle ; Rebecca C. Fitzgerald ; Sarah E. Bohndiek. Design and validation of a near-infrared fluorescence endoscope for detection of early esophageal malignancy. Journal of Biomedical Optics. doi:10.1117/1.JBO.21.8.08400

About Cancer Research UK

  • Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
  • Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
  • Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
  • Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years.
  • Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
  • Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.cancerresearchuk.org. Follow us on Twitter and Facebook.

Cancer Research UK

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...